These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines. Dobaño C; Rogers WO; Gowda K; Doolan DL Immunol Lett; 2007 Aug; 111(2):92-102. PubMed ID: 17604849 [TBL] [Abstract][Full Text] [Related]
4. Immune selection in murine tumors. Ph.d thesis. Svane IM; Engel AM APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251 [TBL] [Abstract][Full Text] [Related]
6. MHC class I antigen presentation--recently trimmed and well presented. Flutter B; Gao B Cell Mol Immunol; 2004 Feb; 1(1):22-30. PubMed ID: 16212917 [TBL] [Abstract][Full Text] [Related]
7. Translating cell biology in vitro to immunity in vivo. Boes M; Ploegh HL Nature; 2004 Jul; 430(6996):264-71. PubMed ID: 15241425 [TBL] [Abstract][Full Text] [Related]
8. Recent advances in antigen processing and presentation. Jensen PE Nat Immunol; 2007 Oct; 8(10):1041-8. PubMed ID: 17878914 [TBL] [Abstract][Full Text] [Related]
9. Stress presents a problem for dendritic cells: corticosterone and the fate of MHC class I antigen processing and presentation. Truckenmiller ME; Bonneau RH; Norbury CC Brain Behav Immun; 2006 May; 20(3):210-8. PubMed ID: 16504465 [TBL] [Abstract][Full Text] [Related]
10. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769 [TBL] [Abstract][Full Text] [Related]
11. New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases. Haque A; Blum JS J Biol Regul Homeost Agents; 2005; 19(3-4):93-104. PubMed ID: 16602623 [TBL] [Abstract][Full Text] [Related]
12. Toward a molecular explanation for cross-presentation of antigens to the immune system. Khor B; Makar RS Transfus Med Rev; 2008 Jul; 22(3):188-201. PubMed ID: 18572095 [TBL] [Abstract][Full Text] [Related]
13. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use. Engelhard VH; Bullock TN; Colella TA; Mullins DW Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498 [TBL] [Abstract][Full Text] [Related]
14. Lack of fair play in the T cell response. Lanzavecchia A Nat Immunol; 2002 Jan; 3(1):9-10. PubMed ID: 11753400 [No Abstract] [Full Text] [Related]
15. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Holling TM; Schooten E; van Den Elsen PJ Hum Immunol; 2004 Apr; 65(4):282-90. PubMed ID: 15120183 [TBL] [Abstract][Full Text] [Related]
16. DNA vaccination: antigen presentation and the induction of immunity. Shedlock DJ; Weiner DB J Leukoc Biol; 2000 Dec; 68(6):793-806. PubMed ID: 11129646 [TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts). Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976 [TBL] [Abstract][Full Text] [Related]
18. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Anderson HA; Hiltbold EM; Roche PA Nat Immunol; 2000 Aug; 1(2):156-62. PubMed ID: 11248809 [TBL] [Abstract][Full Text] [Related]